Contact Pfizer Media Relations
This information is intended for media professionals.
This information is intended for media professionals only. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may ONLY respond to calls and emails from professional journalists.
If you are not a journalist, please visit the Contact Page and consult the appropriate Pfizer contact.
Phone: (212) 573-1226
For specific media inquiries:
Europe/Africa/Middle East, email wwce@pfizer.com
You can also visit our Pfizer Worldwide Web Sites.
| Contact |
Responsibility |
Key Focus Areas / Issues (Not all-inclusive) |
|---|---|---|
| Ray Kerins W: 212-733-9203 C: 917-324-0080 Ray.Kerins@pfizer.com |
Vice President, External Affairs & Worldwide Communications | |
| Chris Loder W: 212-733-7897 C: 347-453-8199 Christopher.Loder@pfizer.com |
Head of Media Relations - United States | Litigation; Counterfeiting; Oncology |
| Anne Wilson W: 212-733-5017 C: 202-297-7661 Anne.E.Wilson@pfizer.com |
Head Medical & Science Media Relations | |
| Kristen Neese W: 212-733-8926 C: 646-299-2526 Kristen.E.Neese@pfizer.com |
Head Regulatory & Policy Media Relations | |
| Joan Campion W: 212-733-2798 C: 201-761-9384 Joan.Campion@pfizer.com |
Corporate/Financial Media Relations | Finance; Earnings/SEC Filings; Corporate Governance; Business Development |
| Mackay Jimeson W: 212-733-2324 C: 347-439-5647 Mackay.Jimeson@pfizer.com |
Primary Care | Lyrica, Celebrex, Spiriva, Toviaz, Dimebon, Apixiban, Tanezumab, Lipitor, Viagra, Chantix |
| Gwen Fisher W: 484-865-5160 C: 215-407-1548 Gwen.Fisher@pfizer.com |
Specialty Care | Prevnar, Prevenar 13, Tygacil, Revatio, Geodon, Enbrel, JAK-3 inhibitors |
| Rick Chambers W: 269-833-6387 C:269-760-0770 Richard.T.Chambers@pfizer.com |
GGlobal Manufacturing; Global Engineering; U.S. Regional Support | Environmental; Manufacturing sites |
| Rick Goulart W: 212-733-7457 C: 860-501-3391 Rick.Goulart@pfizer.com |
Animal Health | |
| Samantha Cummis W: 212-733-6924 C: 917-679-8413 Samantha.Cummis@pfizer.com |
Business Development, Strategy & Innovation | |
| Tyrene Frederick-Mack W: 212-733-3848 C: 917-327-7821 Tyrene.Frederick-Mack@pfizer.com |
Latin America | |
| Neena Moorjani W: 852 2287 9939 C: 852 9038 0150 Neena.Moorjani@pfizer.com |
Asia Pacific |
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
Stock Symbol: PFE Stock Exchange: NYSE
Stock Quote at: Sep 3 2010 4:00PM
| Last 16.46 | Change 0.06 |
| %Change | 0.37 | Vol. | 33,124,845 |
| Day High | 16.59 | 52 Wk. High | 20.36 |
| Day Low | 16.38 | 52 Wk. Low | 14.00 |
| Open | 16.47 | Mkt. Cap(Bil) | 132.31 |
| Prev. Close | 16.40 |
Pfizer. Where science comes to life. Where life meets science.
- View the Interactive 2009 Annual Report
- Learn more about Our Path Forward
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Privacy Policy
Copyright © 2002–2010 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
